Two of Sarepta’s DMD drugs fail to meet primary endpoint in confirmatory trial
Despite the trial failure, Sarepta will still seek full approval of AMONDYS 45 and VYONDYS 53 from the FDA.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
